Michael Burgess, MD, PhD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Gene Therapy Pain Management Photodynamic Therapy Targeted Therapy
Dr. Michael Burgess graduated from David Geffen School of Medicine at UCLA in 2007. He did his residency in internal medicine at the University of California, San Francisco. He also completed a fellowship in hematology and medical oncology in 2012 at the University of California, San Francisco. He is a board-certified medical oncologist and currently practices at the UCSF Medical Center. During his vast clinical experience, he contributed to several research publications.
David Geffen School of Medicine at UCLA
Medical School
UCSF
Residency
UCSF
Fellowship
American Board of Internal Medicine - Oncology
UCSF Medical Center
Languages: English/Spanish
(415) 353-1037
505 Parnassus Ave
San Francisco, California 94143
Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.
Wong, J. C.,Weinfurtner, K. M.,Alzamora, M. D.,Kogan, S. C.,Burgess, M. R.,Zhang, Y.,Nakitandwe, J.,Ma, J.,Cheng, J.,Chen, S. C.,Ho, T. T.,Flach, J.,Reynaud, D.,Passeg...; Elife. 2015 Jul 21.
See more >>Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR Hwang E Firestone AJ Huang T Xu J Zuber J Bohin N Wen T Kogan SC Haigis KM Sampath D Lowe S Shannon K Li Q; Blood. 2014 Dec 18 .
See more >>MAGI-2 scaffold protein is critical for kidney barrier function.
Balbas MD Burgess MR Murali R Wongvipat J Skaggs BJ Mundel P Weins A Sawyers CL; Proc Natl Acad Sci U S A. 2014 Sep 30 .
See more >>